Biocon Limited

Cidara Therapeutics, Inc.

Biolink Life Sciences, Inc.

Napp Pharmaceutical Group Limited

Seachaid Pharmaceuticals, Inc.

Navdeep Balkrishna Malkar

Balasingam Radhakrishnan

Nnochiri Ekwuribe

Kenneth D James

Monica Puskas

Michelle Ferro

Diti Aggarwal

Deanna J Nelson

Kenneth Duke James, Jr

Anuradha Vaidya

Karen Polowy

Christopher Patrick Laudeman

Leo Pavliv

David Hughes

Kenneth Bartizal

Martin Patrick Hughes

Paul Daruwala

Walter C Holberg, Iii

Nnochiri N Ekwuribe

Balasingham Radhakrishnan

Kenneth Duke James

Nnochiril N Ekwuribe

Karen Puskas

Nnochirii N Ekwuribe

The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.

Antifungal agents and uses thereof

The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.

Compositions and methods for the treatment of fungal infections

The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug.

Pharmaceutical compositions and uses thereof

An insulin compound coupled to a modifying moiety having a formula:&#x2014;X&#x2014;R&#x2014;Y-PAG-Z&#x2014;R&#x2003;&#x2003;(Formula VI)

Cation complexes of insulin compound conjugates, formulations and uses thereof

An insulin conjugate is disclosed in which insulin is coupled to a modifying moiety of the formula X&#x2014;R&#x2014;Y-PAG-Z&#x2014;Rwherein X, Y, and Z are linking groups, Ris a capping group, and PAG is a carbon chain that incorporates one or more alkylene glycol moieties.

Insulin-oligomer conjugates, formulations and uses thereof

Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.

Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof

The invention provides a complex including a cation and an insulin compound conjugate. The insulin compound conjugate includes insulin compound, such as human insulin or an analog thereof, conjugated to a modifying moiety, such as a polyethylene glycol moiety. The invention also includes solids and pharmaceutical compositions including such complexes, methods of making such complexes, and methods of using such complexes in the treatment of insulin compound deficiencies and other ailments. Further, the invention includes novel insulin compound conjugates and modifying moieties for use in making novel insulin compound conjugates. The invention also includes fatty acid compositions for administration of pharmaceutical agents, such as the novel insulin compound conjugates, and/or the cation-insulin compound conjugate complexes of the invention.

Cation complexes of insulin compound conjugates, formulation and uses thereof

The present invention relates to methods for preparing lithium valproate and administering this compound to a subject in need of treatment with lithium and/or valproate. Pharmaceutical compositions are also provided that are useful therapies for the treatment of neurological, immunological, and viral-mediated disorders in warm-blooded mammals.

Methods for the preparation, formulation and use of lithium valproate

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, subcutaneous, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.

Natriuretic compounds, conjugates, and uses thereof

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.

Growing community of inventors

Cary, NC, United States of America

Navdeep Balkrishna Malkar